GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Liabilities-to-Assets

BCAL Diagnostics (ASX:BDX) Liabilities-to-Assets : 0.28 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. BCAL Diagnostics's Total Liabilities for the quarter that ended in Dec. 2023 was A$2.36 Mil. BCAL Diagnostics's Total Assets for the quarter that ended in Dec. 2023 was A$8.42 Mil. Therefore, BCAL Diagnostics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.28.


BCAL Diagnostics Liabilities-to-Assets Historical Data

The historical data trend for BCAL Diagnostics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Liabilities-to-Assets Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
Liabilities-to-Assets
0.09 0.38

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Liabilities-to-Assets Get a 7-Day Free Trial 0.03 0.09 0.05 0.38 0.28

Competitive Comparison of BCAL Diagnostics's Liabilities-to-Assets

For the Diagnostics & Research subindustry, BCAL Diagnostics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BCAL Diagnostics's Liabilities-to-Assets Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Liabilities-to-Assets falls into.



BCAL Diagnostics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

BCAL Diagnostics's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Liabilities-to-Assets (A: Jun. 2023 )=Total Liabilities/Total Assets
=3.157/8.371
=0.38

BCAL Diagnostics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=2.355/8.422
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BCAL Diagnostics  (ASX:BDX) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


BCAL Diagnostics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


BCAL Diagnostics (ASX:BDX) Business Description

Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.